Clinical trials: Urinary Bladder Neoplasm
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01089088
- Testing
- cisplatin, gemcitabine hydrochloride, sunitinib malate
- Where
- 16 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Cardiff University
Advanced Solid Tumor, Advanced Malignant Neoplasm
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C…
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
- Trial name
- NCT04585750
- Testing
- rezatapopt, pembrolizumab
- Where
- 76 sites in United States, Australia and 7 more
- Volunteers
- 300 people
- Sponsor
- PMV Pharmaceuticals, Inc
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01090466
- Testing
- cisplatin, gemcitabine hydrochloride, temsirolimus
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cardiff University
Pancreatic Cancer, Small Bowel Cancer
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
The objective of this expanded access program is to provide ulixertinib (BVD-523) for compassionate use in advanced cancer patients with MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF…
- Conditions
- Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma
- Trial name
- NCT04566393
- Testing
- Ulixertinib (BVD-523)
- Where
- 26 sites in United States
- Sponsor
- xCures
Bladder Carcinoma, Hernia
PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit)
This randomized phase III trial studies how well biologic mesh works in preventing parastomal hernia in patients with bladder cancer who are undergoing radical cystectomy, or removal of the bladder, and ileal conduit diversion.
- Trial name
- NCT02439060
- Testing
- Acellular Cadaveric Dermal Matrix
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of Southern California
Bladder Cancer
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy (RT) uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00055601
- Testing
- cisplatin, fluorouracil, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Cancer
Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic.
- Trial name
- CALIBER (NCT02070120)
- Testing
- Mitomycin C, Surgical Management
- Where
- 38 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Urinary Bladder Cancer
Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer
The main objective of the CanMoRe study is to evaluate the impact of a standardized and individually adapted exercise intervention in Primary Health Care aiming at improving physical function (primary outcome) and habitual…
- Trial name
- CanMoRe (NCT03998579)
- Testing
- The CanMoRe programme, Home exercise
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
Bladder Cancer
Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002490
- Testing
- BCG vaccine, mitomycin C, radiation therapy
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
Phase II trial to study the effectiveness of combining trastuzumab with combination chemotherapy in treating patients who have locally recurrent or metastatic urinary tract cancer.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder
- Trial name
- NCT00005831
- Testing
- trastuzumab, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Care of Cancer Patients With Bowel Injury Caused by Radiation Therapy to the Pelvis
RATIONALE: A step-by-step procedure may help health care practitioners diagnose and treat cancer patients with bowel injury symptoms caused by radiation therapy.
- Trial name
- NCT00737230
- Testing
- educational intervention, questionnaire administration, assessment of therapy complications
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Stage III Bladder Cancer, Stage IV Bladder Cancer
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
Randomized phase III trial to compare the effectiveness of immediate adjuvant chemotherapy with that of adjuvant chemotherapy given when the cancer returns in treating patients who have undergone a radical cystectomy for stage…
- Conditions
- Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT00028756
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride, vinblastine sulfate
- Volunteers
- 285 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non Muscle Invasive Bladder Cancer
Comparison of BCG RIVM and Russian Strains for Treating Non-Muscle-Invasive Bladder Cancer (NMIBC)
The goal of this clinical trial is to compare the efficacy and safety of two Bacillus Calmette-Guérin (BCG) substrains (RIVM and Russian) in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC)…
- Trial name
- NCT06767982
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people
- Sponsor
- Ankara University
Bladder Cancer
Urine-based Detection of Non-muscle Invasive Bladder
Non-muscle invasive bladder cancer (NMIBC), which comprises approximately 75% of bladder tumors, has the highest recurrence rate of all cancers, with around 70% of the patients developing local recurrences, despite elaborated…
- Trial name
- SOLUSION (NCT03962933)
- Where
- Denmark
- Volunteers
- 196 people
- Sponsor
- Nessn Azawi
Validity-evidence for a Simulator-based Test, Virtual Simulation
Development and Validation of a Simulator-based Test in Transurethral Resection of Bladder Tumors
Bladder cancer (BC) is the seventh most common cancer in men worldwide and fourth most common cancer among Danish men. BC is estimated to be the most cost expensive cancer pr. patient life.
- Conditions
- Validity-evidence for a Simulator-based Test, Virtual Simulation, Bladder Cancer, Surgical Skill Training
- Trial name
- NCT03863028
- Testing
- Simulation training
- Where
- 2 sites in Denmark
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Urothelial Cancer
A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
Enfortumab vedotin (or PADCEV Injection) is a treatment for cancer in the bladder lining (urothelial cancer). PADCEV Injection is now available to treat this cancer.
- Trial name
- NCT06011954
- Testing
- Enfortumab Vedotin
- Where
- 22 sites in South Korea
- Volunteers
- 228 people
- Sponsor
- Astellas Pharma Korea, Inc.
Cancer, Bladder, Cystostomy; Complications
Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy
The aim of this study is to evaluate the outcome of perioperative immune-nutrition with glutamine, arginine and fish oil in patients undergoing radical cystectomy as regards to enhancement of healing, increasing immunity and…
- Trial name
- NCT05822518
- Testing
- Neo-mune powder (otsuka pharmaceutical), Dipeptiven solution (Fresenius Kabi pharmaceutical)
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Menoufia University
Survivors of Childhood Cancer, Bladder Dysfunction
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
The over-arching aim of this study is to evaluate the effects of two specific anti-cancer chemotherapies, vincristine and doxorubicin, on bladder function and urine composition.
- Trial name
- NCT04993859
- Testing
- Non-invasive Urodynamic Test (niUDS), Urinary proteomic screen, Dysfunctional Voiding Symptom Score Survey (DVSS)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Colorado, Denver
Urinary Bladder Neoplasms
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.
- Trial name
- IRE (NCT02430623)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou